Melissa B. Epperly net worth and biography

Melissa Epperly Biography and Net Worth

Director of Roivant Sciences

Melissa Epperly has served as Director of Roivant since 2022. Ms. Epperly most recently served as Chief Financial Officer at Zentalis Pharmaceuticals, Inc., from September 2019 to April 2024. Prior to that, she served as Chief Financial Officer of PsiOxus Therapeutics Ltd., a clinical-stage gene therapy cancer company, from June 2018 to August 2019, and as Chief Financial Officer and Head of Business Development at R-Pharm US, a commercial-stage oncology company, from October 2015 to June 2018. Ms. Epperly also served as a Director at Anchorage Capital Group, a credit-focused hedge fund from August 2012 to September 2015. Ms. Epperly holds a B.A. in Biochemistry and Economics from the University of Virginia and an M.B.A from Harvard Business School.

What is Melissa B. Epperly's net worth?: The estimated net worth of Melissa B. Epperly is at least $439.35 thousand as of March 16th, 2026. Ms. Epperly owns 15,804 shares of Roivant Sciences stock worth more than $439,351 as of March 19th. This net worth estimate does not reflect any other investments that Ms. Epperly may own. Learn More about Melissa B. Epperly's net worth.
How do I contact Melissa B. Epperly?: The corporate mailing address for Ms. Epperly and other Roivant Sciences executives is Clarendon House, 2 Church Street, Hamilton Parish HM 11. Roivant Sciences can also be reached via phone at 44-20-7400-3347 and via email at [email protected]. Learn More on Melissa B. Epperly's contact information.
Has Melissa B. Epperly been buying or selling shares of Roivant Sciences?: Within the last three months, Melissa B. Epperly has sold $1,200,573.48 in Roivant Sciences stock. Most recently, Melissa B. Epperly sold 41,861 shares of the business's stock in a transaction on Monday, March 16th. The shares were sold at an average price of $28.68, for a transaction totalling $1,200,573.48. Following the completion of the sale, the director now directly owns 15,804 shares of the company's stock, valued at $453,258.72. Learn More on Melissa B. Epperly's trading history.
Who are Roivant Sciences' active insiders?: Roivant Sciences' insider roster includes Melissa Epperly (Director), Matthew Gline (CEO), Daniel Gold (Director), Rakhi Kumar (CAO), Keith Manchester (Director), Richard Pulik (CFO), Vivek Ramaswamy (Major Shareholder), Mayukh Sukhatme (President and Chief Investment Officer), Frank Torti (Insider), and Eric Venker (COO). Learn More on Roivant Sciences' active insiders.
Are insiders buying or selling shares of Roivant Sciences?: In the last year, Roivant Sciences insiders bought shares 2 times. They purchased a total of 16,669,981 shares worth more than $350,049,943.05. In the last year, insiders at the sold shares 55 times. They sold a total of 26,257,898 shares worth more than $510,098,927.04. The most recent insider tranaction occured on March, 16th when Director Melissa B Epperly sold 41,861 shares worth more than $1,200,573.48. Insiders at Roivant Sciences own 10.8% of the company. Learn More about insider trades at Roivant Sciences.
Information on this page was last updated on 3/16/2026.

Melissa B. Epperly Insider Trading History at Roivant Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/16/2026	Sell	41,861	$28.68	$1,200,573.48	15,804

Melissa B. Epperly Buying and Selling Activity at Roivant Sciences

Roivant Sciences Company Overview

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Today's Range

Now: $27.53

$27.65

$28.33

50 Day Range

MA: $25.68

$21.14

$29.72

2 Week Range

Now: $27.53

$8.73

$30.33

Volume

4,345,944 shs

Average Volume

5,719,963 shs

Market Capitalization

$19.71 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.17